Abstract
With increasing knowledge of cellular networks of gene and molecular interactions, and their alterations in GBM (glioblastoma multiforme), it is now possible to apply methods of Network Pharmacology (NP) to predict candidate drug targets for this malignant brain tumor. NP requires the development of mathematical methods for network stability and perturbation analysis to identify sensitive and druggable network components, as well as computational platforms to carry out in silico simulations of therapeutic interventions. This review focuses on the three most frequently deregulated GBM pathways involving membrane receptor tyrosine kinases, p53, and Rb. Structural features of these networks that may confound targeted therapies are discussed.
Keywords: Network pharmacology, glioblastoma, p53, Myc, Rb, receptor tyrosine kinase
Current Drug Discovery Technologies
Title:Network Pharmacology of Glioblastoma
Volume: 10 Issue: 2
Author(s): Baltazar D. Aguda
Affiliation:
Keywords: Network pharmacology, glioblastoma, p53, Myc, Rb, receptor tyrosine kinase
Abstract: With increasing knowledge of cellular networks of gene and molecular interactions, and their alterations in GBM (glioblastoma multiforme), it is now possible to apply methods of Network Pharmacology (NP) to predict candidate drug targets for this malignant brain tumor. NP requires the development of mathematical methods for network stability and perturbation analysis to identify sensitive and druggable network components, as well as computational platforms to carry out in silico simulations of therapeutic interventions. This review focuses on the three most frequently deregulated GBM pathways involving membrane receptor tyrosine kinases, p53, and Rb. Structural features of these networks that may confound targeted therapies are discussed.
Export Options
About this article
Cite this article as:
D. Aguda Baltazar, Network Pharmacology of Glioblastoma, Current Drug Discovery Technologies 2013; 10 (2) . https://dx.doi.org/10.2174/1570163811310020005
DOI https://dx.doi.org/10.2174/1570163811310020005 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Preparation, Chemical and Electrical Characterizations of Lipid Nanoparticles Loaded with Dihydroxybenzophenone
Medicinal Chemistry Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design PREFACE
Anti-Cancer Agents in Medicinal Chemistry Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Bioprocessing of Baculovirus Vectors: A Review
Current Gene Therapy Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Nanoparticles in Melanoma
Current Medicinal Chemistry Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design <i>In Vitro</i> Characteristics of Glioma Cells Targeting by OX26-modified Liposomal Cisplatin
Letters in Drug Design & Discovery Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry